Cancer Research

Cancer Research
  • Pininvest Analysis

Our selection for cancer research attempts to mirror some of the transformative forces at play in biotechnology

Clinical stage research remains a significant market segment as large pharmaceutical enterprises see value in farming out some of their research – read our theme dedicated to clinical companies (to be published soon)

But, conversely, large biopharma companies, often highly valued by the market because of their growth expectations, may consider integration of former or current partner firms to diversify their drug pipeline – possibly guaranteeing a significant part of future earnings of future drugs to former owners, to clinch a deal …

Read our note

Cancer Research • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Momentum Vol. Risk Contrib. MDD
 
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 33.17 2.2 B -49.3% Weak Up 68%   12% -62%
Bristol-Myers Squibb BMY NYSE Health Care Drug Manufacturers - Diversified USD 66.83 150 B 18.5% Neutral 21%   2% -11%
Geron GERN NASDAQ Health Care Drug Manufacturers - Diversified USD 1.70 541 M -12.8% Neutral 61%   12% -43%
Incyte Corporation INCY NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 84.93 19 B -22.0% Neutral 35%   6% -31%
Inovio Pharmaceuticals INO NASDAQ Health Care Biopharmaceuticals USD 8.64 1.8 B -43.5% Strong Up 129%   26% -80%
Lumos Pharma LUMO NASDAQ Health Care Biopharmaceuticals USD 10.93 91 M -34.5% Neutral 64%   7% -73%
Merrimack Pharmaceuticals, Inc. MACK NASDAQ Health Care Biopharmaceuticals USD 6.36 85 M 81.2% Neutral 75%   9% -31%
Seagen SGEN NASDAQ Health Care Oncology USD 158.30 29 B -7.4% Weak Up 42%   7% -36%
Siemens Healthineers SMMNY OTC Health Care Medical Devices USD 29.76 - 24.7% Neutral 24%   2% -20%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 2.63 565 M -25.9% Sharp Down 76%   17% -53%